From mice to men: An assessment of preclinical model systems for the study of vitiligo
Clin Immunol. 2024 Mar 8:110171. doi: 10.1016/j.clim.2024.110171. Online ahead of print.ABSTRACTVitiligo is an autoimmune skin disease of multiple etiology, for which there is no complete cure. This chronic depigmentation is characterized by epidermal melanocyte loss, and causes disfigurement and significant psychosocial distress. Mouse models have been extensively employed to further our understanding of complex disease mechanisms in vitiligo, as well as to provide a preclinical platform for clinical interventional research on potential treatment strategies in humans. The current mouse models can be categorized into three...
Source: Clinical Immunology - March 10, 2024 Category: Allergy & Immunology Authors: Wei Wu Xinju Wang Kaiqiao He Chunying Li Shuli Li Source Type: research
From mice to men: An assessment of preclinical model systems for the study of vitiligo
Clin Immunol. 2024 Mar 8:110171. doi: 10.1016/j.clim.2024.110171. Online ahead of print.ABSTRACTVitiligo is an autoimmune skin disease of multiple etiology, for which there is no complete cure. This chronic depigmentation is characterized by epidermal melanocyte loss, and causes disfigurement and significant psychosocial distress. Mouse models have been extensively employed to further our understanding of complex disease mechanisms in vitiligo, as well as to provide a preclinical platform for clinical interventional research on potential treatment strategies in humans. The current mouse models can be categorized into three...
Source: Clinical Immunology - March 10, 2024 Category: Allergy & Immunology Authors: Wei Wu Xinju Wang Kaiqiao He Chunying Li Shuli Li Source Type: research
From mice to men: An assessment of preclinical model systems for the study of vitiligo
Clin Immunol. 2024 Mar 8:110171. doi: 10.1016/j.clim.2024.110171. Online ahead of print.ABSTRACTVitiligo is an autoimmune skin disease of multiple etiology, for which there is no complete cure. This chronic depigmentation is characterized by epidermal melanocyte loss, and causes disfigurement and significant psychosocial distress. Mouse models have been extensively employed to further our understanding of complex disease mechanisms in vitiligo, as well as to provide a preclinical platform for clinical interventional research on potential treatment strategies in humans. The current mouse models can be categorized into three...
Source: Clinical Immunology - March 10, 2024 Category: Allergy & Immunology Authors: Wei Wu Xinju Wang Kaiqiao He Chunying Li Shuli Li Source Type: research
Epidemiologic and clinical differences between early-onset and later-onset childhood vitiligo, a retrospective cohort study
(Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - March 9, 2024 Category: Dermatology Authors: Li Meiyun, Xie Li, Liu Xiaoyi, Deng Dan Source Type: research
Epidemiologic and clinical differences between early-onset and later-onset childhood vitiligo: A retrospective cohort study
This study aims to elucidate the epidemiologic and clinical disparities between early-onset ( ≤3 years of age) and later-onset (3-12 years of age) CV. (Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - March 9, 2024 Category: Dermatology Authors: Li Meiyun, Xie Li, Liu Xiaoyi, Deng Dan Tags: Research letter Source Type: research
308 nm excimer laser and tacrolimus ointment in the treatment of facial vitiligo: a systematic review and meta-analysis
This study aimed to investigate the effects and safety of 308 nm excimer laser (308 nm EL) and tacrolimus ointment (TO) in the treatment of facial vitiligo (FV). We searched Cochrane Library, PUBMED, EMBASE, CNKI, and WANGFANG from inception to June 1, 2023. Outcomes included overall response rate (ORR), total adverse reaction rate (TARR), recurrence rate a t 3-month (RR-3) and recurrence rate at 6-month (RR-6). The outcome data were presented as odds ratios (OR) with 95% confidence intervals (CI). The risk of bias was assessed by Cochrane risk-of-bias tool and data analysis was performed by RevMan 5.4 software. This st...
Source: Lasers in Medical Science - March 8, 2024 Category: Laser Surgery Source Type: research
Pigmented purpuric dermatosis (Majocchi type) in a patient with vitiligo
Key Clinical MessagePigmented purpuric dermatosis is diagnosed clinically and does not require skin biopsy. However, in cases where rashes mimic cutaneous vasculitis, skin biopsies should be done to confirm the diagnosis, especially in patients who have underlying autoimmune disease. (Source: Clinical Case Reports)
Source: Clinical Case Reports - March 7, 2024 Category: General Medicine Authors: Nattanicha Chaisrimaneepan,
Hataitip Manupeerapun,
Thunyaporn Khoruamklang Tags: CASE IMAGE Source Type: research
Identification of a novel TSC1 gene variant in a patient with atypical vitiligo-like skin lesions: Unveiling the hidden tuberous sclerosis complex
CONCLUSION: The detection of this novel pathogenic TSC1 variant in the patient with atypical vitiligo-like skin lesions enrolled in our study ultimately resulted in the diagnosis of TSC. As a result, our study contributes to expanding the mutational spectrum of the TSC1 gene and refining the genotype-phenotype map of TSC.PMID:38439608 | DOI:10.1002/mgg3.2403 (Source: Molecular Medicine)
Source: Molecular Medicine - March 5, 2024 Category: Molecular Biology Authors: Linli Liu Yanbo Wang Zhengzhong Zhang Chunshui Yu Jin Chen Source Type: research
Topical antibiotics limit depigmentation in a mouse model of vitiligo
Pigment Cell Melanoma Res. 2024 Mar 4. doi: 10.1111/pcmr.13164. Online ahead of print.ABSTRACTOral neomycin administration impacts the gut microbiome and delays vitiligo development in mice, and topical antibiotics may likewise allow the microbiome to preserve skin health and delay depigmentation. Here, we examined the effects of 6-week topical antibiotic treatment on vitiligo-prone pmel-1 mice. Bacitracin, Neosporin, or Vaseline were applied to one denuded flank, while the contralateral flank was treated with Vaseline in all mice. Ventral depigmentation was quantified weekly. We found that topical Neosporin treatment sign...
Source: Pigment Cell and Melanoma Research - March 5, 2024 Category: Cytology Authors: Ahmed Ahmed Touni Rachel Sohn Cormac Cosgrove Rohan S Shivde Emilia R Dellacecca Rasha T A Abdel-Aziz Kettil Cedercreutz Stefan J Green Hossam Abdel-Wahab I Caroline Le Poole Source Type: research
Topical antibiotics limit depigmentation in a mouse model of vitiligo
Pigment Cell Melanoma Res. 2024 Mar 4. doi: 10.1111/pcmr.13164. Online ahead of print.ABSTRACTOral neomycin administration impacts the gut microbiome and delays vitiligo development in mice, and topical antibiotics may likewise allow the microbiome to preserve skin health and delay depigmentation. Here, we examined the effects of 6-week topical antibiotic treatment on vitiligo-prone pmel-1 mice. Bacitracin, Neosporin, or Vaseline were applied to one denuded flank, while the contralateral flank was treated with Vaseline in all mice. Ventral depigmentation was quantified weekly. We found that topical Neosporin treatment sign...
Source: Cell Research - March 5, 2024 Category: Cytology Authors: Ahmed Ahmed Touni Rachel Sohn Cormac Cosgrove Rohan S Shivde Emilia R Dellacecca Rasha T A Abdel-Aziz Kettil Cedercreutz Stefan J Green Hossam Abdel-Wahab I Caroline Le Poole Source Type: research
Novel Clinical Applications of Topical Ruxolitinib: A Case Series
J Drugs Dermatol. 2024 Mar 1;23(3):188-190. doi: 10.36849/jdd.7696.ABSTRACTTopical ruxolitinib, a potent Janus kinase (JAK) inhibitor, has shown significant efficacy in treating inflammatory skin conditions. While its use has already been established in atopic dermatitis and vitiligo, recent reports suggest its potential efficacy in treating other dermatoses. Specifically, topical ruxolitinib may be an effective treatment option for refractory dermatological conditions that are inflammation-driven with dysregulated activity of cytokines implicated in the JAK/STAT pathway. In this case series, we present four novel clinical...
Source: Journal of Drugs in Dermatology - March 5, 2024 Category: Dermatology Authors: Melissa P Zundell Roudha Al-Dehneem Teresa Song Jenna Yousif Alice B Gottlieb Source Type: research
Identification of a novel TSC1 gene variant in a patient with atypical vitiligo-like skin lesions: Unveiling the hidden tuberous sclerosis complex
CONCLUSION: The detection of this novel pathogenic TSC1 variant in the patient with atypical vitiligo-like skin lesions enrolled in our study ultimately resulted in the diagnosis of TSC. As a result, our study contributes to expanding the mutational spectrum of the TSC1 gene and refining the genotype-phenotype map of TSC.PMID:38439608 | PMC:PMC10912791 | DOI:10.1002/mgg3.2403 (Source: Molecular Medicine)
Source: Molecular Medicine - March 5, 2024 Category: Molecular Biology Authors: Linli Liu Yanbo Wang Zhengzhong Zhang Chunshui Yu Jin Chen Source Type: research
